GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annji Pharmaceutical Co Ltd (ROCO:7754) » Definitions » Total Stockholders Equity

Annji Pharmaceutical Co (ROCO:7754) Total Stockholders Equity : NT$809.4 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Annji Pharmaceutical Co Total Stockholders Equity?

Annji Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Jun. 2024 was NT$809.4 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Annji Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2024 was NT$8.65. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Annji Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.07.

Annji Pharmaceutical Co Total Stockholders Equity Historical Data

The historical data trend for Annji Pharmaceutical Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annji Pharmaceutical Co Total Stockholders Equity Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Total Stockholders Equity
650.13 510.51 925.04

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
Total Stockholders Equity 650.13 510.51 - 925.04 809.42

Annji Pharmaceutical Co  (ROCO:7754) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Annji Pharmaceutical Co's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(809.421-0)/93.5745
=8.65

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Annji Pharmaceutical Co's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.885 + 52.374) / 809.421
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Annji Pharmaceutical Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Annji Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annji Pharmaceutical Co Ltd (ROCO:7754) » Definitions » Total Stockholders Equity
Comparable Companies
ROCO:6986 TPE:1733 ROCO:6580 ROCO:6892 ROCO:7808 ROCO:6926 ROCO:4169 ROCO:6676 ROCO:6634 ROCO:4911 VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Website
https://www.ajpharm.com
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.

Annji Pharmaceutical Co Headlines

No Headlines